Table 2 Adjusted HR of CCP implementation to predict all-cause and cardiovascular mortality.
All-Cause Mortality HR (95% CI) | P-value* | Cardiovascular Mortality HR (95% CI) | P-value** | |
|---|---|---|---|---|
Age | 1.07 (1.05–1.08) | <0.01 | 1.04 (1.03–1.06) | <0.01 |
Male | 1.24 (1.02–1.51) | 0.03 | 1.13 (0.83–1.52) | 0.45 |
ST elevated myocardial infarction | 0.75 (0.62–0.91) | <0.01 | 0.72 (0.54–0.97) | <0.01 |
Killip class | <0.01 | <0.01 | ||
I | Reference | Reference | ||
II | 1.11 (0.89–1.40) | 0.36 | 1.30 (0.90–1.87) | 0.16 |
III | 1.49 (1.18–1.87) | <0.01 | 1.89 (1.32–2.69) | <0.01 |
IV | 1.16 (0.77–1.77) | 0.48 | 1.41 (0.74–2.70) | 0.30 |
Smoker | 0.95 (0.80–1.14) | 0.60 | 0.84 (0.64–1.12) | 0.24 |
Past medical history | ||||
Hypertension | 1.03 (0.85–1.25) | 0.77 | 1.40 (1.02–1.92) | 0.04 |
Diabetes mellitus | 1.27 (1.06–1.52) | 0.01 | 1.19 (0.90–1.58) | 0.22 |
Hyperlipidemia | 0.92 (0.77–1.10) | 0.34 | 0.96 (0.72–1.27) | 0.76 |
ACS | 1.09 (0.76–1.55) | 0.66 | 0.90 (0.51–1.61) | 0.73 |
Chronic kidney disease | 2.18 (1.79–2.65) | <0.01 | 2.04 (1.49–2.78) | <0.01 |
Creatine kinase | 0.79 (0.65–0.95) | 0.02 | 0.77 (0.57–1.05) | 0.10 |
LVEF | <0.01 | <0.01 | ||
≥50% | Reference | Reference | ||
36–49% | 1.26 (1.01–1.58) | 0.04 | 1.07 (0.73–1.56) | 0.75 |
≤35% | 1.88 (1.51–2.33) | <0.01 | 2.36 (1.68–3.30) | <0.01 |
Coronary angiography | ||||
Left main disease | 0.73 (0.50–1.06) | 0.10 | 0.84 (0.49–1.46) | 0.54 |
Triple vessel disease | 0.67 (0.54–0.84) | <0.01 | 0.40 (0.27–0.60) | <0.01 |
Implementation of CCP | 0.75 (0.62–0.91) | <0.01 | 0.62 (0.46–0.84) | <0.01 |
